CURE’s liver cancer page features the latest cancer news and updates on liver cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in liver cancer.
October 18th 2024
From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.
September 26th 2024
Younger Adults, Women with Cancer Respond Less Well to Immunotherapy with Checkpoint Inhibitors
September 16th 2020Younger and female patients with a variety of cancer types tend to have strong immune systems that naturally fight an array of cancer cells. The tumor cells the immune system doesn’t destroy are the most evasive, both to the immune system and medications that boost its activity, and this makes checkpoint inhibitor immunotherapy less effective in this population.
Uneven Access to Preventive Medicine Could Explain Rising Racial Inequity in Liver Cancer Death Rate
August 21st 2020After lifesaving medicine became available to treat hepatitis C virus, a risk factor for liver cancer, racial inequities in the death rate from the malignancy began a steady upward climb.
Numerous Quality-of-Life Disturbances Affect Patients with Cholangiocarcinoma, Survey Finds
July 27th 2020A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives.
FDA's Approval of Pemazyre a 'Huge Milestone' for Patients with Cholangiocarinoma
May 5th 2020The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.
FDA Grants Accelerated Approval to Opdivo-Yervoy Combo for Advanced HCC
March 11th 2020The Food and Drug Administration granted an accelerated approval to the combination of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with Nexavar.
In Early Recurrent Liver Cancer, Surgery and Radiofrequency Ablation Spark Similar Survival Benefits
December 19th 2019Radiofrequency ablation was statistically on par with surgery when it came to survival after an early recurrence of liver cancer, but surgery provided more benefit if the disease was a bit more advanced.
Precise Radiation to the Tumor Is Safe and Effective in Treating Patients with Liver Cancer
December 17th 2019Patients with hepatocellular carcinoma whose tumors couldn’t be surgically removed lived longer and experienced few side effects after stereotactic body radiotherapy, according to phase 2 study findings.
FDA Grants Priority Review to Pemigatinib for Cholangiocarcinoma Treatment
December 3rd 2019The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.
Proton Beam Therapy: A Less Toxic Option in Liver Cancer
November 21st 2019While radiation therapy may be a common alternative for inoperable hepatocellular carcinoma, two new studies suggest that proton radiation therapy may offer the same benefits as the more traditionally used photon radiation therapy, with less toxicity.